On March 25, 2020, the Office of the U.S. Trade Representative (USTR) published a Federal Register Notice requesting public comments on possible further modifications to remove Section 301 duties from additional Chinese-origin medical-care products. The USTR invites comments from interested persons with respect to whether a particular product covered by Section 301 duties on Chinese goods is needed to respond to the COVID-19 outbreak. The comment docket will remain open at least until June 25, 2020, and may be extended as appropriate.
The USTR is requesting that each comment identify the particular product of concern and explain precisely how the product relates to the response to the COVID-19 outbreak. For example, a comment may address whether a product is directly used to treat COVID-19 or to limit the outbreak, and/or whether the product is used in the production of needed medical-care products.
The USTR is accepting comments regarding any product covered by the Section 301 duties, regardless of whether the product is subject to a pending or denied exclusion request.